)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vivoryon Therapeutics
Vivoryon Therapeutics (VVY) investor relations material
Vivoryon Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Priority is securing funding or a partnership for varoglutamstat’s planned Phase 2b study in advanced diabetic kidney disease (DKD); alternative strategic options are also under review.
Rights to varoglutamstat in Greater China returned from Simcere, consolidating global rights and supporting a kidney-disease focus.
Financial highlights
Nine-month revenue was €0, unchanged YoY; net loss narrowed to €4.8 million from €7.6 million.
R&D expense fell to €2.3 million from €3.7 million, mainly on €1.0 million lower kidney-related clinical development and analysis costs.
G&A expense declined to €2.7 million from €4.0 million, reflecting lower share-based personnel costs and cost-saving measures.
Cash and cash equivalents were €1.7 million at September 30, 2026, versus €5.6 million at December 31, 2025.
Outlook and guidance
Updated cash runway extends into the second half of December 2026, subject to unforeseen circumstances and excluding SEPA proceeds and other potential financing.
Phase 2b DKD study initiation and future studies depend on additional funding and/or a partnership.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vivoryon Therapeutics
- Phase 2 data show robust eGFR improvement and safety, supporting a pivotal DKD trial.VVY
Corporate presentation - Licensing talks advance as varoglutamstat shows strong results and cash runway into Q4 2026.VVYQ2 2026
- Strong clinical progress and reduced losses, but future hinges on new funding or partnerships.VVYQ1 2026
- Strong Phase 2 data, new patent, and reduced net loss position for Phase 2b DKD trial.VVYQ4 2025
- Varoglutamstat showed robust eGFR improvement and safety, targeting advanced DKD unmet needs.VVYInvestor presentation
- Varoglutamstat showed strong, sustained kidney benefits in Phase II, driving DKD focus and funding needs.VVYQ3 2024
- Half year 2024 results and a Kidney Disease KOL event are set for September, with strong late-stage CKD data.VVYStatus Update
- Varoglutamstat's kidney benefits drive a strategic pivot to DKD, with Phase II study planned.VVYQ2 2024
- Robust, sustained kidney benefits in diabetes, with phase II DKD trials and expert support planned.VVYR&D Update
Next Vivoryon Therapeutics earnings date
Q4 202623 Apr, 2027
Vivoryon Therapeutics
Next Vivoryon Therapeutics earnings date
Q4 202623 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vivoryon Therapeutics N.V., previously known as Probiodrug, is a Germany-based clinical-stage biopharmaceutical company. It specializes in the discovery and development of therapies for patients suffering from age-related diseases, with a primary focus on Alzheimer’s disease and cancer immune checkpoint inhibition. The company leverages its expertise in understanding post-translational modifications to develop small molecule medications that modulate the activity and stability of proteins altered in disease settings. The company is headquartered in Halle (Saale), Germany, and its shares are listed on the Euronext Amsterdam.